TY - JOUR
T1 - Hepatitis E should be a global public health priority
T2 - recommendations for improving surveillance and prevention
AU - Kirkwood, Carl D.
AU - Dobscha, Katherine R.
AU - Steele, A. Duncan
N1 - Publisher Copyright:
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020
Y1 - 2020
N2 - Introduction: Hepatitis E virus (HEV) is an important cause of enterically transmitted viral hepatitis and a significant contributor to maternal mortality in endemic regions around the world, yet the global response has been limited. HEV is a disease of poverty, and the populations experiencing the greatest burden of HEV-associated illness are not benefitting from existing interventions, including WASH strategies and immunization. Areas Covered: Though a vaccine exists (HEV 239, Hecolin®, Xiamen Innovax Biotech, China), it is only licensed and available in the private market in China and has yet to be prequalified by the WHO for use in endemic settings and outbreaks. This review of the current state of HEV disease and subsequent recommendations for a coordinated public health response are intended to guide the global health community towards breaking the current ‘vicious cycle,’ in which a lack of data prevents actions that would improve health outcomes. Expert opinion: Vaccine implementation in future outbreaks, targeted studies assessing vaccine effectiveness and immunogenicity in endemic regions and populations, improved understanding of the global burden, and improvements in diagnostic and epidemiologic tools are urgently needed. Strategies for implementing routine vaccination programs, improving water, sanitation, and hygiene in endemic regions.
AB - Introduction: Hepatitis E virus (HEV) is an important cause of enterically transmitted viral hepatitis and a significant contributor to maternal mortality in endemic regions around the world, yet the global response has been limited. HEV is a disease of poverty, and the populations experiencing the greatest burden of HEV-associated illness are not benefitting from existing interventions, including WASH strategies and immunization. Areas Covered: Though a vaccine exists (HEV 239, Hecolin®, Xiamen Innovax Biotech, China), it is only licensed and available in the private market in China and has yet to be prequalified by the WHO for use in endemic settings and outbreaks. This review of the current state of HEV disease and subsequent recommendations for a coordinated public health response are intended to guide the global health community towards breaking the current ‘vicious cycle,’ in which a lack of data prevents actions that would improve health outcomes. Expert opinion: Vaccine implementation in future outbreaks, targeted studies assessing vaccine effectiveness and immunogenicity in endemic regions and populations, improved understanding of the global burden, and improvements in diagnostic and epidemiologic tools are urgently needed. Strategies for implementing routine vaccination programs, improving water, sanitation, and hygiene in endemic regions.
KW - Viral hepatitis
KW - hepatitis E
KW - hepatitis vaccine
KW - hev
UR - http://www.scopus.com/inward/record.url?scp=85100045189&partnerID=8YFLogxK
U2 - 10.1080/14760584.2020.1874930
DO - 10.1080/14760584.2020.1874930
M3 - Review article
C2 - 33441054
AN - SCOPUS:85100045189
SN - 1476-0584
VL - 19
SP - 1129
EP - 1140
JO - Expert Review of Vaccines
JF - Expert Review of Vaccines
IS - 12
ER -